<?xml version="1.0" encoding="UTF-8"?>
<p>QT prolongation has been reported in cohorts of patients treated with these COVID-19 drugs, with a prevalence of up to 90% in some reports.
 <sup>
  <xref rid="bibr17" ref-type="bibr">17</xref>,
  <xref rid="bibr18" ref-type="bibr">18</xref>
 </sup> Individual cases of QT prolongation-induced TdP in COVID-19 patients have also been reported.
 <sup>
  <xref rid="bibr17" ref-type="bibr">17</xref>,
  <xref rid="bibr19" ref-type="bibr">19</xref>
 </sup> A recent meta-analysis showed that although there was no significant benefit of hydroxychloroquine on viral clearance, a significant increase in mortality was observed in patients with COVID-19 treated with hydroxychloroquine, compared to the control group.
 <sup>
  <xref rid="bibr20" ref-type="bibr">20</xref>
 </sup> Rosenberg et al reported that cardiac arrest occurred more likely in patients receiving a combination of hydroxychloroquine and azithromycin (adjusted OR, 2.13 [95% CI, 1.12-4.05]), while the risk was lower when hydroxychloroquine or azithromycin were used alone.
 <sup>
  <xref rid="bibr21" ref-type="bibr">21</xref>
 </sup>
</p>
